Notice: This company has been marked as potentially delisted and may not be actively trading. Merrimack Pharmaceuticals (MACK) News Today Add Compare Share Share Headlines Stock AnalysisDividendEarningsHeadlinesInsider TradesOwnershipTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period College football connection: Easton’s Hutchison posts 2 TDs in F&M victorySeptember 25, 2024 | msn.comMACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q1 2024May 16, 2024 | investorplace.comMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Increases Dividend to $15.10 Per ShareMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced a dividend on Thursday, May 16th. Investors of record on Tuesday, May 21st will be paid a dividend of 15.10 per share by the biopharmaceutical company on Friday, May 17th. This represents a yield of 99.87%. The ex-dividend date of this dividend is Monday, May 20th. This is a positive change from Merrimack Pharmaceuticals's previous dividend of $1.50.May 16, 2024 | marketbeat.comMerrimack Pharmaceuticals Shareholders OK Dissolution PlanMay 10, 2024 | marketwatch.comMerrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common StockMay 10, 2024 | businesswire.comMerrimack Pharmaceuticals intends to declare $15.10 dividendMay 9, 2024 | msn.comMerrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of DissolutionMay 9, 2024 | finance.yahoo.comMerrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of DissolutionApril 30, 2024 | businesswire.comMACK Merrimack Pharmaceuticals, Inc.April 20, 2024 | seekingalpha.comDiagonal starts up with $128M to make better ‘activator’ antibody drugsApril 3, 2024 | finance.yahoo.comMerrimack Receives $225 Million Milestone Payment from IpsenMarch 27, 2024 | businesswire.comMerrimack Pharmaceuticals (NASDAQ:MACK) Shares Cross Above 200 Day Moving Average of $13.19Merrimack Pharmaceuticals (NASDAQ:MACK) Stock Crosses Above Two Hundred Day Moving Average of $13.19March 26, 2024 | marketbeat.comMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Sees Large Drop in Short InterestMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK - Get Free Report) was the recipient of a large drop in short interest in February. As of February 29th, there was short interest totalling 774,100 shares, a drop of 5.9% from the February 14th total of 822,900 shares. Based on an average daily volume of 92,100 shares, the days-to-cover ratio is presently 8.4 days.March 18, 2024 | marketbeat.comStocks Gain as U.S. Unemployment Report Bolsters the Outlook for Fed Rate CutsMarch 8, 2024 | msn.comMACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q4 2023March 8, 2024 | investorplace.comMerrimack Reports Full Year 2023 Financial ResultsMarch 7, 2024 | businesswire.comMerrimack Pharmaceuticals (NASDAQ:MACK) Shares Cross Above Two Hundred Day Moving Average of $12.93Merrimack Pharmaceuticals (NASDAQ:MACK) Stock Price Crosses Above 200 Day Moving Average of $12.93March 5, 2024 | marketbeat.comMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is definitely on the radar of hedge funds investors who own 35% of the companyMarch 4, 2024 | finance.yahoo.comMerrimack Pharmaceuticals Stock (NASDAQ:MACK), Analyst Ratings, Price Targets, PredictionsFebruary 22, 2024 | benzinga.comMACK Mar 2024 14.000 putFebruary 17, 2024 | finance.yahoo.comMACK Mar 2024 4.000 putFebruary 17, 2024 | finance.yahoo.comOnKure Announces the Appointment of Samuel Agresta, M.D., as Chief Medical OfficerFebruary 15, 2024 | markets.businessinsider.comMACK Feb 2024 16.000 putFebruary 14, 2024 | finance.yahoo.comIpsen drug approved by FDA for early pancreatic cancerFebruary 14, 2024 | finance.yahoo.comThe S&P 500, Dow, Nasdaq are down as traders push back forecasts for interest rate cutsFebruary 13, 2024 | msn.comMerrimack Pharmaceuticals to Hold Meeting on Corporate DissolutionFebruary 13, 2024 | marketwatch.comMerrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)February 13, 2024 | finance.yahoo.comMerrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)February 13, 2024 | businesswire.comMerrimack Pharmaceuticals (NASDAQ:MACK) Stock Price Passes Above 200 Day Moving Average of $12.65Merrimack Pharmaceuticals (NASDAQ:MACK) Shares Cross Above Two Hundred Day Moving Average of $12.65February 13, 2024 | marketbeat.comMerrimack Pharmaceuticals (NASDAQ:MACK) Stock Price Passes Above 200 Day Moving Average of $12.55Merrimack Pharmaceuticals (NASDAQ:MACK) Shares Cross Above Two Hundred Day Moving Average of $12.55January 31, 2024 | marketbeat.comMerrimack Pharmaceuticals (NASDAQ:MACK) Upgraded at StockNews.comStockNews.com raised shares of Merrimack Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Wednesday.January 31, 2024 | marketbeat.comMerrimack Pharmaceuticals (NASDAQ:MACK) Downgraded by StockNews.comStockNews.com downgraded shares of Merrimack Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Tuesday.January 23, 2024 | marketbeat.comMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Director Eric Andersen Purchases 857 SharesMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK - Get Free Report) Director Eric Andersen acquired 857 shares of the stock in a transaction dated Thursday, December 28th. The shares were bought at an average price of $13.35 per share, with a total value of $11,440.95. Following the completion of the transaction, the director now directly owns 534,008 shares of the company's stock, valued at $7,129,006.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.December 28, 2023 | marketbeat.comMerrimack Pharmaceuticals (NASDAQ:MACK) Upgraded to Hold at StockNews.comStockNews.com raised shares of Merrimack Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Wednesday.December 27, 2023 | marketbeat.com$2M Bet On Ford? Check Out These 4 Stocks Insiders Are BuyingDecember 12, 2023 | msn.comWe're Interested To See How Merrimack Pharmaceuticals (NASDAQ:MACK) Uses Its Cash Hoard To GrowDecember 10, 2023 | finance.yahoo.comMerrimack Pharmaceuticals Inc MACKNovember 10, 2023 | morningstar.comMerrimack Reports Third Quarter 2023 Financial ResultsNovember 2, 2023 | finance.yahoo.comOnconova Expands Leadership Team with Two Key AppointmentsOctober 24, 2023 | stockhouse.comThe Fight Against Pancreatic Cancer Just Gained a New Ally with $200M VC FirmOctober 20, 2023 | theglobeandmail.comWestern Standard LLC Boosts Stake in Merrimack Pharmaceuticals IncAugust 15, 2023 | finance.yahoo.comOnconova Therapeutics, Inc. (NASDAQ:ONTX) Q2 2023 Earnings Call TranscriptAugust 13, 2023 | insidermonkey.comMerrimack Reports Second Quarter 2023 Financial ResultsAugust 3, 2023 | finance.yahoo.comPharming Group N.V.: Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the BoardJuly 18, 2023 | finanznachrichten.dePharming to nominate industry leader Dr. Richard Peters as new Chairman of the BoardJuly 18, 2023 | finance.yahoo.comMerrimack Pharmaceuticals (NASDAQ:MACK) Stock Rating Lowered by StockNews.comStockNews.com downgraded Merrimack Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Friday.July 7, 2023 | marketbeat.comMerrimack Pharmaceuticals (NASDAQ:MACK) Downgraded to "Sell" at StockNews.comStockNews.com cut Merrimack Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Friday.June 23, 2023 | marketbeat.comMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is 22Nw LP's 6th Largest Position22Nw LP lowered its holdings in shares of Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK - Get Rating) by 17.5% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,015,048 shares of the biopharmaceutical company's stock after selMay 26, 2023 | marketbeat.comShort Interest in Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Increases By 6.7%Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK - Get Rating) was the target of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 904,700 shares, a growth of 6.7% from the March 31st total of 847,700 shares. Based on an average daily volume of 91,700 shares, the days-to-cover ratio is currently 9.9 days. Approximately 6.9% of the company's stock are short sold.May 2, 2023 | marketbeat.comRetail investors account for 38% of Merrimack Pharmaceuticals, Inc.'s (NASDAQ:MACK) ownership, while hedge funds account for 33%April 19, 2023 | finance.yahoo.com Get Merrimack Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MACK and its competitors with MarketBeat's FREE daily newsletter. Email Address Let’s be blunt (Ad)Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! Check out the $100 Challenge now MACK Media Mentions By Week MACK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MACK News Sentiment▼0.920.49▲Average Medical News Sentiment MACK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MACK Articles This Week▼00▲MACK Articles Average Week Get Merrimack Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MACK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IRWD News EBS News RIGL News SGMO News XOMA News CDXS News VNDA News LXRX News VSTM News ACHV News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MACK) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merrimack Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Merrimack Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MACK Stock Alerts